⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Verisian and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Verisian
↗London, United Kingdom
Verisian is a London-based health-tech startup that provides an information infrastructure for clinical trials, leveraging AI and full study traceability. The company's platform is designed to automate clinical trial validation, data integration, and submission documentation, aiming to reduce time-to-market for new therapies by improving transparency and reducing regulatory inquiry cycles.
Verisian's suite of tools—including Validator, Builder, Pooler, and Tracer—allows sponsors, CROs, and regulators to monitor studies in real-time, automate SDTM and ADaM validation, and ensure data integrity. By connecting specifications, data, code, and results, Verisian seeks to make clinical trial analysis more efficient, transparent, and reliable.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:-
Industry:Digital Health
Sub-Industry:Clinical Trial Analytics / HealthTech
SIZE & FINANCIALS
Employees:1-50
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$5.6M
Investors:Seedcamp, Superseed, Recode Health, Magnetic
0
CORPORATE STRUCTURE
Key Partnerships:CDISC (Collaborating to refactor the CDISC Open Rules Engine - CORE), Lindus Health (Deployment of AI-based SDTM define-xml automation)
COMPETITION
Position:Emerging
Competitors:Saama, Lila Sciences, BeaconCure
LEADERSHIP
Key Executives:
Tomás Sabat Stöfsel - CEO and Co-Founder
Henning Kuich - CTO and Co-Founder
Scientific Founders:Tomás Sabat Stöfsel, Henning Kuich
LINKS
Website:verisian.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Verisian. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.